Condensed Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
|
Common Stock |
Treasury Stock |
Additional Paid-In Capital |
Accumulated Other Comprehensive Income |
Accumulated Deficit |
Total |
| Balance at Dec. 31, 2022 |
$ 45
|
$ (172)
|
$ 68,574,621
|
|
$ (48,265,324)
|
$ 20,309,170
|
| Balance (in Shares) at Dec. 31, 2022 |
446,290
|
|
|
|
|
|
| Balance (in Shares) at Dec. 31, 2022 |
|
1,550
|
|
|
|
|
| Stock-based compensation expense recovery |
|
|
160,010
|
|
|
160,010
|
| Vesting of restricted stock |
|
|
299,656
|
|
|
299,656
|
| Vesting of restricted stock (in Shares) |
4,334
|
|
|
|
|
|
| Issuance of common stock through exercise of stock options |
|
|
70,889
|
|
|
70,889
|
| Issuance of common stock through exercise of stock options (in Shares) |
3,545
|
|
|
|
|
|
| Unrealized loss on available-for-sale securities |
|
|
|
840
|
|
840
|
| Net loss |
|
|
|
|
(11,099,488)
|
(11,099,488)
|
| Balance at Dec. 31, 2023 |
$ 45
|
$ (172)
|
69,105,176
|
840
|
(59,364,812)
|
$ 9,741,077
|
| Balance (in Shares) at Dec. 31, 2023 |
454,169
|
|
|
|
|
454,169
|
| Balance (in Shares) at Dec. 31, 2023 |
|
1,550
|
|
|
|
1,550
|
| Stock-based compensation expense recovery |
|
|
45,871
|
|
|
$ 45,871
|
| Repurchase of common stock purchase warrants exercisable under PIPE Warrants |
|
|
(52,500)
|
|
|
(52,500)
|
| Issuance of common stock in connection with At The Market Offering Agreement |
$ 2
|
|
138,485
|
|
|
138,487
|
| Issuance of common stock in connection with At The Market Offering Agreement (in Shares) |
18,899
|
|
|
|
|
|
| Offering costs in connection with At the Market Offering Agreement |
|
|
(204,845)
|
|
|
(204,845)
|
| Vesting of restricted stock |
|
|
48,054
|
|
|
48,054
|
| Vesting of restricted stock (in Shares) |
438
|
|
|
|
|
|
| Unrealized loss on available-for-sale securities |
|
|
|
(799)
|
|
(799)
|
| Net loss |
|
|
|
|
(2,902,117)
|
(2,902,117)
|
| Balance at Mar. 31, 2024 |
$ 47
|
$ (172)
|
69,080,241
|
41
|
(62,266,929)
|
6,813,228
|
| Balance (in Shares) at Mar. 31, 2024 |
473,506
|
|
|
|
|
|
| Balance (in Shares) at Mar. 31, 2024 |
|
1,550
|
|
|
|
|
| Balance at Dec. 31, 2023 |
$ 45
|
$ (172)
|
69,105,176
|
840
|
(59,364,812)
|
$ 9,741,077
|
| Balance (in Shares) at Dec. 31, 2023 |
454,169
|
|
|
|
|
454,169
|
| Balance (in Shares) at Dec. 31, 2023 |
|
1,550
|
|
|
|
1,550
|
| Unrealized loss on available-for-sale securities |
|
|
|
|
|
$ (840)
|
| Net loss |
|
|
|
|
|
(5,011,141)
|
| Balance at Jun. 30, 2024 |
$ 65
|
$ (172)
|
70,465,344
|
|
(64,375,953)
|
6,089,284
|
| Balance (in Shares) at Jun. 30, 2024 |
654,789
|
|
|
|
|
|
| Balance (in Shares) at Jun. 30, 2024 |
|
1,550
|
|
|
|
|
| Balance at Dec. 31, 2023 |
$ 45
|
$ (172)
|
69,105,176
|
840
|
(59,364,812)
|
$ 9,741,077
|
| Balance (in Shares) at Dec. 31, 2023 |
454,169
|
|
|
|
|
454,169
|
| Balance (in Shares) at Dec. 31, 2023 |
|
1,550
|
|
|
|
1,550
|
| Stock-based compensation expense recovery |
|
|
101,844
|
|
|
$ 101,844
|
| Repurchase of common stock purchase warrants exercisable under PIPE Warrants |
0
|
|
(52,500)
|
|
|
(52,500)
|
| Issuance of common stock |
$ 13
|
|
398,429
|
|
|
398,442
|
| Issuance of common stock (in Shares) |
132,814
|
|
|
|
|
|
| Issuance of common stock in connection with At The Market Offering Agreement |
$ 20
|
|
1,494,394
|
|
|
1,494,414
|
| Issuance of common stock in connection with At The Market Offering Agreement (in Shares) |
199,004
|
|
|
|
|
|
| Issuance of common stock through exercise of prefunded warrants |
$ 74
|
|
4,599,948
|
|
|
4,600,022
|
| Issuance of common stock through exercise of prefunded warrants (in Shares) |
734,221
|
|
|
|
|
|
| Offering costs in connection with At the Market Offering Agreement |
|
|
(255,288)
|
|
|
(255,288)
|
| Offering costs in connection with issuance of common shares and warrants |
|
|
(366,189)
|
|
|
(366,189)
|
| Reverse stock split adjustment |
$ 18
|
|
(18)
|
|
|
|
| Reverse stock split adjustment (in Shares) |
174,738
|
|
|
|
|
|
| Vesting of restricted stock |
|
|
147,831
|
|
|
147,831
|
| Vesting of restricted stock (in Shares) |
1,958
|
|
|
|
|
|
| Issuance of common stock through exercise of stock options |
|
|
|
|
|
|
| Unrealized loss on available-for-sale securities |
|
|
|
(840)
|
|
(840)
|
| Net loss |
|
|
|
|
(12,497,805)
|
(12,497,805)
|
| Balance at Dec. 31, 2024 |
$ 170
|
$ (172)
|
75,173,627
|
|
(71,862,617)
|
$ 3,311,008
|
| Balance (in Shares) at Dec. 31, 2024 |
1,696,904
|
|
|
|
|
1,696,904
|
| Balance (in Shares) at Dec. 31, 2024 |
|
1,550
|
|
|
|
1,550
|
| Balance at Mar. 31, 2024 |
$ 47
|
$ (172)
|
69,080,241
|
41
|
(62,266,929)
|
$ 6,813,228
|
| Balance (in Shares) at Mar. 31, 2024 |
473,506
|
|
|
|
|
|
| Balance (in Shares) at Mar. 31, 2024 |
|
1,550
|
|
|
|
|
| Stock-based compensation expense recovery |
|
|
34,834
|
|
|
34,834
|
| Issuance of common stock in connection with At The Market Offering Agreement |
$ 18
|
|
1,355,909
|
|
|
1,355,927
|
| Issuance of common stock in connection with At The Market Offering Agreement (in Shares) |
180,105
|
|
|
|
|
|
| Offering costs in connection with At the Market Offering Agreement |
|
|
(50,443)
|
|
|
(50,443)
|
| Vesting of restricted stock |
|
|
44,803
|
|
|
44,803
|
| Vesting of restricted stock (in Shares) |
1,178
|
|
|
|
|
|
| Unrealized loss on available-for-sale securities |
|
|
|
(41)
|
|
(41)
|
| Net loss |
|
|
|
|
(2,109,024)
|
(2,109,024)
|
| Balance at Jun. 30, 2024 |
$ 65
|
$ (172)
|
70,465,344
|
|
(64,375,953)
|
6,089,284
|
| Balance (in Shares) at Jun. 30, 2024 |
654,789
|
|
|
|
|
|
| Balance (in Shares) at Jun. 30, 2024 |
|
1,550
|
|
|
|
|
| Balance at Dec. 31, 2024 |
$ 170
|
$ (172)
|
75,173,627
|
|
(71,862,617)
|
$ 3,311,008
|
| Balance (in Shares) at Dec. 31, 2024 |
1,696,904
|
|
|
|
|
1,696,904
|
| Balance (in Shares) at Dec. 31, 2024 |
|
1,550
|
|
|
|
1,550
|
| Stock-based compensation expense recovery |
|
|
1,158
|
|
|
$ 1,158
|
| Issuance of common stock through exercise of prefunded warrants |
$ 80
|
|
(80)
|
|
|
|
| Issuance of common stock through exercise of prefunded warrants (in Shares) |
799,631
|
|
|
|
|
|
| Vesting of restricted stock |
|
|
14,743
|
|
|
14,743
|
| Vesting of restricted stock (in Shares) |
152
|
|
|
|
|
|
| Net loss |
|
|
|
|
(1,658,396)
|
(1,658,396)
|
| Balance at Mar. 31, 2025 |
$ 250
|
$ (172)
|
75,189,448
|
|
(73,521,013)
|
1,668,513
|
| Balance (in Shares) at Mar. 31, 2025 |
2,496,687
|
|
|
|
|
|
| Balance (in Shares) at Mar. 31, 2025 |
|
1,550
|
|
|
|
|
| Balance at Dec. 31, 2024 |
$ 170
|
$ (172)
|
75,173,627
|
|
(71,862,617)
|
$ 3,311,008
|
| Balance (in Shares) at Dec. 31, 2024 |
1,696,904
|
|
|
|
|
1,696,904
|
| Balance (in Shares) at Dec. 31, 2024 |
|
1,550
|
|
|
|
1,550
|
| Issuance of common stock through exercise of stock options |
|
|
|
|
|
|
| Unrealized loss on available-for-sale securities |
|
|
|
|
|
|
| Net loss |
|
|
|
|
|
(2,705,639)
|
| Balance at Jun. 30, 2025 |
$ 250
|
$ (172)
|
75,190,151
|
|
(74,568,256)
|
$ 621,973
|
| Balance (in Shares) at Jun. 30, 2025 |
2,496,873
|
|
|
|
|
2,496,873
|
| Balance (in Shares) at Jun. 30, 2025 |
|
1,550
|
|
|
|
1,550
|
| Balance at Mar. 31, 2025 |
$ 250
|
$ (172)
|
75,189,448
|
|
(73,521,013)
|
$ 1,668,513
|
| Balance (in Shares) at Mar. 31, 2025 |
2,496,687
|
|
|
|
|
|
| Balance (in Shares) at Mar. 31, 2025 |
|
1,550
|
|
|
|
|
| Stock-based compensation expense recovery |
|
|
(66)
|
|
|
(66)
|
| Offering costs in connection with the on-going Public Offering |
|
|
(1,100)
|
|
|
(1,100)
|
| Vesting of restricted stock |
|
|
1,869
|
|
|
1,869
|
| Vesting of restricted stock (in Shares) |
186
|
|
|
|
|
|
| Unrealized loss on available-for-sale securities |
|
|
|
|
|
|
| Net loss |
|
|
|
|
(1,047,243)
|
(1,047,243)
|
| Balance at Jun. 30, 2025 |
$ 250
|
$ (172)
|
$ 75,190,151
|
|
$ (74,568,256)
|
$ 621,973
|
| Balance (in Shares) at Jun. 30, 2025 |
2,496,873
|
|
|
|
|
2,496,873
|
| Balance (in Shares) at Jun. 30, 2025 |
|
1,550
|
|
|
|
1,550
|